Monday, July 22, 2019 12:05:43 PM
(See biotechnician’s post...”something of GREAT VALUE”)
This, from the Shelf Prospectus (pg 15 middle)
“Nevada Anti-Takeover Law and Charter and Bylaws Provisions
Nevada Revised Statutes sections 78.378 to 78.3793 provide state regulation over the acquisition of a controlling interest in certain Nevada corporations unless the articles of incorporation or bylaws of the corporation provide that the provisions of these sections do not apply. The statute creates a number of restrictions on the ability of a person or entity to acquire control of a Nevada company by setting down certain rules of conduct and voting restrictions in any acquisition attempt, among other things. The statute is limited to corporations that are organized in the state of Nevada and that have 200 or more shareholders, at least 100 of whom are shareholders of record and residents of the state of Nevada; and do business in the state of Nevada directly or through an affiliated corporation. Because of these conditions, the statute does not apply to our Company.
There are no provisions in our articles of incorporation or our bylaws that would delay, defer or prevent a change in control of our Company.”
The company spells out that the Nevada Statute to prevent takeover, does not apply to us.
Further,
Last sentence set off alone, for emphasis.
I asked a SEC reg filing lawyer to explain what this means. I thought the poison pill (shareholders rights plan) was put in place exactly to “slow down an unwanted change in control of the company”, by means of adding the extra warrant we would get for each share at a specified price, etc to offset a hostile maneuver. HOSTILE, key word. We are still protected from that, although, we now seem to appear less and less concerned with that eventuality, as of latest filing. Cool.
He said the wording is very interesting in this case. Normally, we would only need to answer in a Prospectus that we are incorporated in Nevada and there are Statutes which may or may not affect the takeover of our company. (Let reviewers do the work)
Likewise, we could have stated that our Articles of Incorporation provide for measures in the event of an unwanted “hostile” takeover.
(Let the reviewers read through.)
We needn’t have spelled it out to be in compliance, after all this is a public document.
We were under no obligation in a boilerplate S-3 to provide this level of detail. (Remember that our CEO is called “non-transparent to the point of being a scammer”, by some.” This is unbelievably transparent - WE ARE A SITTING DUCK!”)
We are a sitting duck - if the change in control is a DESIRED one. On favorable terms.
According to the lawyer, if they use this language, they are doing 2 things with one stone: they are providing the necessary information to the SEC - but in a publicly viewable doc which all other companies can see. Also, the language is such that, legally, if a change in control were to occur, on favorable terms, the SEC would have to review that deal before approving the necessary structure and filings to make sure there are no hitches.
Since this language will have already been viewed and approved once already by SEC, it would be pointed out again and having passed muster, they would be quicker to see - NO HITCHES.
Know anybody who likes to compress time, money, steps by preplanning the necessary language and terms to avoid confusion...? I do.
Friendly partner in the wings or Bidding war looms. Once that shelf is tapped - You will know it!
This should be the center of the “dilution” discussion.
Additionally, we were eligible to file this shelf 3 years from our uplist date, since this requires 3 years of financials. We uplisted Oct. 30, 2015. Fiscal year began Nov 1, 2015. On Nov 1, 2018, we had sufficient financial data to file. We did not, until now.
Missling knew we would need capitalization further down the road for growth. He managed the LPC/Cantor offerings and Australian discount and foundation subsidies to get us to where we are now. So, as many ask, with readouts due soon for 2 trials, why file shelf now?
“We cannot delay, deter, or prevent a change in control of our company.”
(Other interesting words in the Prospectus - it’s public! Please read.)
Partnership at worst, bidding war at best.
Looks like Someone’s Got This!
Bio
Recent AVXL News
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:05:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:06 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:31:07 PM
- Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/07/2024 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024 • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:01:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM